Jefferies: 'we think BIIB stock could climb higher on the resiliency of the commercial franchise'
Tweet Send to a Friend
Jefferies analyst Andrew Tsai reiterated a Buy rating and $210.00 price target on Biogen (NASDAQ: BIIB).The analyst comments "Topline details ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
